new oral anticoagulants | PPT
Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
MASTER DAPT | Terumo Interventional Systems
JCM | Free Full-Text | Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis | European Journal of Clinical Pharmacology
Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
New strategies for effective treatment of vitamin K antagonist‐associated bleeding - ScienceDirect
Direct Oral Anticoagulants: A User's Guide | Consultant360
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67%
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series - The Lancet Haematology
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model - ISTH Congress Abstracts
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial | Haematologica
Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis - Nikhil Nair Hariharan, Kashyap Patel, Omaike Sikder, Kanjana S
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
